查詢結果分析
相關文獻
- The Molecular Mechanism and WHO-endorsed Diagnosis of Rifampicin Resistance in Mycobacterium tuberculosis
- 臺灣某區域醫院分枝桿菌(Mycobacteria)的抗藥性調查
- Antibiotic Susceptibility Analysis of Mycobacterial Infections in Central Taiwan
- 北部某醫學中心分離出Mycobacterium abscessus Complex進行藥物感受性試驗之趨勢評估:2018~2023年研究結果
- 臺灣分離之多重抗藥性結核桿菌rpoB基因分析
- Drug Resistance Patterns of Tuberculosis in Taiwan
- 雞肉檢體中沙門氏桿菌快速檢驗方法之探討
- 偵測多種抗藥性結核桿菌的最新發展
- 寄生蟲的抗藥性現象面面觀
- Comparison of the Sensitivity and Specificity of an Automatic Ligase Chain Reaction Assay System with a One-Step Polymerase Chain Reaction Assay in the Diagnosis of Mycobacterium Tuberculosis Complex
頁籤選單縮合
| 題 名 | The Molecular Mechanism and WHO-endorsed Diagnosis of Rifampicin Resistance in Mycobacterium tuberculosis=結核分枝桿菌對立汎黴素的抗藥機轉及WHO認可的快速檢驗立汎黴素抗藥株之方法 |
|---|---|
| 作 者 | 洪育芝; 蘇伯琦; | 書刊名 | Journal of Biomedical & Laboratory Sciences |
| 卷 期 | 27:4 2015.12[民104.12] |
| 頁 次 | 頁115-124 |
| 分類號 | 418.283 |
| 關鍵詞 | 結核分枝桿菌; 立汎黴素; 抗藥性; rpoB基因; 快速檢驗; Mycobacterium tuberculosis; Rifampicin resistant; rpoB gene; Rapid test; |
| 語 文 | 英文(English) |
| 中文摘要 | 立汎黴素(rifampicin)是治療結核病的第一線藥物之一,細菌對立汎黴素產生抗藥性最常見的原因是細菌rpoB基因產生突變,導致其編碼(encode)產生核糖核酸聚合酶(RNA polymerase)的β次單元(β–subunit)也發生突變。而這些突變大多集中在一段長度為81-bp DNA區域,稱為rifampicin resistance-determining region(簡稱RRDR),但也有報導發現有些抗立汎黴素的抗藥菌株則是在RRDR以外的區域及輸出幫浦(efflux pumps)發生突變所造成。本篇綜論介紹rpoB基因的點突變與立汎黴素抗藥性機轉之關聯性及六種世界衛生組織已認可的快速檢驗抗立汎黴素菌株的方法:microscopic observation of drug susceptibility (MODS), nitrate reductase assay (NRA), colorimetricredox indicator (CRI), INNO-LiPA Rif. TB, Xpert® MTB/RIF test以及GenoType®MTBDRplus (包括MTBDR) assay。 |
| 英文摘要 | Rifampicin is one of first-line drugs used in the treatment of tuberculosis (TB). Increasing rifampicin resistance hampers effective TB treatment. Resistance to rifampicin is commonly caused by mutation in the rpoB gene encoding the β–subunit of RNA polymerase. Mutations of 81-bp rifampicin resistance-determining region (RRDR) of the rpoB gene associate with most of rifampicin resistance in clinical strains. However, mutations outside RRDR and efflux pumps have been reported to be involved in rifampicin resistance. Rapid test for rifampicin resistance is important for improving patient care and decreasing TB transmission. World health organization (WHO) has endorsed rapid phenotypic tests, microscopic observation of drug susceptibility (MODS), nitrate reductase assay (NRA) and colorimetric redox indicator (CRI), and molecular tests, INNO-LiPA Rif. TB, Xpert® MTB/RIF test, GenoType® MTBDR assay and GenoType® MTBDRplus assay, for rifampicin resistance and recommended the use of rapid tests in high risk multidrug-resistant TB (MDR-TB) settings. This review article focuses on the various site mutation in rpoB associated with mycobacterial rifampicin resistance and summarizes the performance of these WHO-endorsed rapid tests for rifampicin resistance. |
本系統中英文摘要資訊取自各篇刊載內容。